Chief Executive Officer
Anthony is a seasoned business executive and entrepreneur, with over 25 years of experience in life sciences, technology, & finance. Prior to joining Immplacate, Anthony was CEO at Spruce Technology, where he led the firm through an extended period of high growth and expansion. In addition, he has held a number of senior level positions with global responsibilities, which include the medical device powerhouse Guidant, where he was involved in various aspects of the cardiovascular portfolio of products. Anthony also serves on the board at East River Biosolutions, Inc., a leading biotechnology firm that specializes in native extracellular matrix (ECM) products for life sciences. He has specialized capabilities in sales, marketing, finance, operations, HR, R&D, and strategy. Anthony holds an MBA from Columbia Business School, Columbia University in New York.
Strategic Dev. Advisor
Strategic Development Advisor
Donna See is a Vice President at Allied Minds (Venture Capital firm), leading the firm’s partnerships with U.S. universities. Donna brings more than 14 years of experience in academic technology transfer, public-private partnerships, and early-stage technology development. She most recently served as Director of Licensing and Director of Strategic Initiatives for Columbia Technology Ventures, an internationally recognized leader in the field of academic tech transfer, and as the Founding Director of the Columbia-Coulter Translational Research Partnership. Prior to Columbia, Donna was Director of Business Development and Technology Transfer at New York-Presbyterian Hospital, forging strategic alliances with government and industry partners to evaluate, develop and acquire new healthcare technologies.
Scientific Co-Founder, Board Member
Gordana Vunjak-Novakovic is the University Professor (Columbia University highest rank), and The Mikati Foundation Professor of Biomedical Engineering and Medicine. She is a leading expert in engineering of human tissues for regenerative medicine, stem cell research (including mesenchymal stem cells), and study of human disease. With over 35,000 citations and h=108, she is one of the most highly cited individuals of all times in all disciplines. She has previously founded three other biotech companies (EpiBone, TARA Biosystems, East River BioSolutions).
Among her recognitions, she is a Fellow of AAAS, a member of the Academia Europaea, National Academy of Engineering, National Academy Medicine, and National Academy of Inventors.
Holly has been involved in biomedical research for 11 years. She is currently a 6th year MD-PhD student in Biomedical Engineering at Columbia University (Presidential Scholar). She has devoted her research to developing mesenchymal stem cell immunotherapies and has expertise in cell therapies, immune modulation, and transplant tolerance. Prior to her MD-PhD, she worked in a stem cell manufacturing lab and has also conducted research in cancer nanotherapeutics. She graduated at the top of her college class at the University of Calgary (Canada), receiving the Muriel Kovitz Prize.
Beyond research, Holly has been engaged in the stem cell field for 5 years as a science writer, contributing monthly articles about the latest developments in regenerative medicine.
Mariko is a PhD student at Columbia University with 4 years of experience in mesenchymal stem cell therapies, induced pluripotent stem cells, and tissue engineering. Due to her impressive record, she was awarded support for her studies by JASSO (a Japanese government-affiliated institution). Mariko has also spent time conducting clinical research.
Mariko is a true global citizen and has been actively involved in several related initiatives. She was president of GlobeMed at Columbia and planned (and participated) in an internship at the partner Ugandan NGO, GWED-G. She was also a Nishimiya Fellow, studying disaster medicine and relief in Fukushima, Japan.